Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in High-risk Triple Negative Breast Cancer
NCT02926196Phase 3Completed
- Sponsor
- Istituto Oncologico Veneto
- Start
- Jun 2016
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Arm Avelumab with Arm Observation (2 arms). Primary endpoints: Disease Free Survival at 5 years and Disease Free Survival in PD-L1-positive patients at 5 years. Started Jun 2016; status: completed.
02
Drugs
avelumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02926196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926196.